Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma.
Nath K, Shekarkhand T, Nemirovsky D, Derkach A, Costa BA, Nishimura N, Farzana T, Rueda C, Chung DJ, Landau HJ, Lahoud OB, Scordo M, Shah GL, Hassoun H, Maclachlan K, Korde N, Shah UA, Tan CR, Hultcrantz M, Giralt SA, Usmani SZ, Shahid Z, Mailankody S, Lesokhin AM. Nath K, et al. Blood Cancer J. 2024 May 31;14(1):88. doi: 10.1038/s41408-024-01043-5. Blood Cancer J. 2024. PMID: 38821925
Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma.
Costa BA, Flynn J, Nishimura N, Devlin SM, Farzana T, Rajeeve S, Chung DJ, Landau HJ, Lahoud OB, Scordo M, Shah GL, Hassoun H, Maclachlan K, Hultcrantz M, Korde N, Lesokhin AM, Shah UA, Tan CR, Giralt SA, Usmani SZ, Nath K, Mailankody S. Costa BA, et al. Blood Cancer J. 2024 May 27;14(1):84. doi: 10.1038/s41408-024-01048-0. Blood Cancer J. 2024. PMID: 38802346 Free PMC article.
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma.
Firestone RS, Socci ND, Shekarkhand T, Zhu M, Ge Qin W, Hultcrantz ML, Mailankody S, Tan CR, Korde N, Lesokhin AM, Hassoun H, Shah UA, Maclachlan KH, Rajeeve S, Landau HJ, Scordo M, Shah GL, Lahoud OB, Giralt SA, Murata K, Usmani SZ, Chung DJ. Firestone RS, et al. Blood. 2024 May 10:blood.2023023557. doi: 10.1182/blood.2023023557. Online ahead of print. Blood. 2024. PMID: 38728378
Unscheduled healthcare interactions in multiple myeloma patients receiving T cell redirection therapies.
Howard AJ, Concepcion I, Wang AX, Hamadeh IS, Hultcrantz ML, Mailankody S, Tan CR, Korde N, Lesokhin AM, Hassoun H, Shah UA, Maclachlan KH, Rajeeve S, Landau HJ, Scordo M, Shah GL, Lahoud OB, Chung DJ, Giralt SA, Usmani SZ, Firestone RS. Howard AJ, et al. Blood Adv. 2024 Apr 12:bloodadvances.2024012871. doi: 10.1182/bloodadvances.2024012871. Online ahead of print. Blood Adv. 2024. PMID: 38621239
Patterns of CRS with Teclistamab in Relapsed/Refractory Multiple Myeloma patients with Prior T-Cell Redirection Therapy.
Hamadeh IS, Shekarkhand T, Rueda CJ, Firestone RS, Wang AX, Korde N, Hultcrantz ML, Lesokhin AM, Mailankody S, Hassoun H, Shah UA, Maclachlan KH, Rajeeve S, Patel D, Shah GL, Scordo M, Lahoud OB, Chung DJ, Landau HJ, Giralt SA, Usmani SZ, Tan CR. Hamadeh IS, et al. Blood Adv. 2024 Apr 10:bloodadvances.2024012724. doi: 10.1182/bloodadvances.2024012724. Online ahead of print. Blood Adv. 2024. PMID: 38598713
Comparison of Infectious Complications with BCMA-directed Therapies in Multiple Myeloma.
Lesokhin A, Nath K, Shekarkhand T, Nemirovsky D, Derkach A, Costa BA, Nishimura N, Farzana T, Rueda C, Chung D, Landau H, Lahoud O, Scordo M, Shah G, Hassoun H, Maclachlan K, Korde N, Shah U, Tan CR, Hultcrantz M, Giralt S, Usmani S, Shahid Z, Mailankody S. Lesokhin A, et al. Res Sq [Preprint]. 2024 Feb 7:rs.3.rs-3911922. doi: 10.21203/rs.3.rs-3911922/v1. Res Sq. 2024. PMID: 38405866 Free PMC article. Preprint.
Current use of CAR T cells to treat multiple myeloma.
Firestone RS, Mailankody S. Firestone RS, et al. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):340-347. doi: 10.1182/hematology.2023000434. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066841 Review.
165 results